Downloadable Resources
Contact
Natera is a global leader in cell-free DNA testing. The company mission is to change the management of disease worldwide with a focus on reproductive health, oncology, and organ transplantation. Signatera is a custom-built, circulating tumor DNA test for molecular residual disease assessment in patients previously diagnosed with cancer. In 2019 it was granted Breakthrough Device Designation by the FDA and Medicare issued a positive draft local coverage determination for stage II-III CRC.
